zemplar
abbott laboratÓrios do brasil ltda - outros prods nao enquadrados em classe terapeutica especif
sermion
laboratÓrios pfizer ltda - nicergolina - vasodilatadores cerebrais
syletyv
accord farmacÊutica ltda - paricalcitol - outros prods nao enquadrados em classe terapeutica especif
cef
uniÃo quÍmica farmacÊutica nacional s/a - cefalexina monoidratada - cefalosporinas
monofer
pfizer brasil ltda - derisomaltose fÉrrica - antianemicos simples
ghemaxan
biomm sa - enoxaparina sÓdica -
cefalexina
ems s/a - cefalexina - cefalosporinas
heptris
mylan laboratorios ltda - enoxaparina sÓdica - antitrombotico
volare
achÉ laboratÓrios farmacÊuticos s.a - enoxaparina sÓdica -
abecma
bristol-myers squibb pharma eeig - idecabtagene vicleucel - multiple myeloma; neoplasms; cancer; neoplasms, plasma cell; hemostatic disorders; vascular diseases; cardiovascular diseases; paraproteinemias; blood protein disorders; hematologic diseases; hemic and lymphatic diseases; hemorrhagic disorders; infectious mononucleosis; lymphoproliferative disorders; immunoproliferative disorders; immune system diseases - agentes antineoplásicos - abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti cd38 antibody and have demonstrated disease progression on the last therapy.